AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15240608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12195057 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber intervertebral fusion cage
Number of subjects: 103
Study 12195057 — intervention group
Group type: COMPARATOR
Intervention: Cloward procedure
Number of subjects: 103
Study 9615264 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 114
Study 9615264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 7915773 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIgG 0.8 g/kg once
Number of subjects: 146
Study 7915773 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIgG 1 g/kg on 2 consecutive days
Number of subjects: 146
Study 7915773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anti-D 25 micrograms/kg on 2 consecutive days
Number of subjects: 146
Study 7915773 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone 4 mg/kg per day with tapering and discontinuation by day 21
Number of subjects: 146
Study 2583258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent melphalan and prednisone (MP)
Number of subjects: 110
Study 2583258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug combination MOCCA
Number of subjects: 110
Study 1103552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipropylacetate (D.P.A.)
Number of subjects: 20
Study 1103552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (NFX) 480 mg/day for 120 days
Number of subjects: 300
Study 31307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BZN) 300 mg/day for 60 days followed by placebo for 60 days
Number of subjects: 300
Study 31307503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 31307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BZN) 150 mg/day for 120 days
Number of subjects: 300
Study 31307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (NFX) 240 mg/day for 120 days
Number of subjects: 300
Study 28608165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4000
Study 28608165 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 4000
Study 28608165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Clopidogrel
Number of subjects: 4000
Study 26243374 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 19
Study 26243374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22905856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg once daily
Number of subjects: 34
Study 22905856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg twice daily
Number of subjects: 34
Study 22905856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20843402 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based home-collaborative dietary education (HCDE) programme, 12 sessions of group counselling
Number of subjects: 474
Study 20843402 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional school classroom education)
Number of subjects: 474
Study 18053050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (5 U)
Number of subjects: 18
Study 18053050 — intervention group
Group type: COMPARATOR
Intervention: BOTOX (2 U)
Number of subjects: 18
Study 17429150 — intervention group
Group type: EXPERIMENTAL
Intervention: Health centres with co-financing model (n=107)
Number of subjects: 138
Study 17429150 — intervention group
Group type: COMPARATOR
Intervention: Health centres without co-financing model (n=31)
Number of subjects: 138
Study 17429150 — intervention group
Group type: EXPERIMENTAL
Intervention: Health centres with co-financing model
Number of subjects: 138
Study 15037702 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study 12791022 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step procedure (Group I)
Number of subjects: 26
Study 12791022 — intervention group
Group type: COMPARATOR
Intervention: Two-step procedure (Group II)
Number of subjects: 26
Study 9243563 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of heroin use at intake
Number of subjects: 0
Study 9243563 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of cocaine use at intake
Number of subjects: 0
Study 9243563 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of heroin use at posttreatment followup
Number of subjects: 0
Study 9243563 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of cocaine use at posttreatment followup
Number of subjects: 0
Study 8515544 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPS) 15 mg.kg‐1 i.v. 60 minutes after CPB
Number of subjects: 40
Study 8515544 — intervention group
Group type: COMPARATOR
Intervention: No Methylprednisolone (MPS) administration
Number of subjects: 40
Study 2835788 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical LTB4 (100-900 ng applied once a week for up to 7 weeks depending on lesion type)
Number of subjects: 36
Study 2835788 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (50% ethanol)
Number of subjects: 36
Study 28941259 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (1–15 mg/day)
Number of subjects: 86
Study 26754832 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1255
Study 26754832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 24239295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic capsules for 7 days
Number of subjects: 60
Study 24239295 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 60
Study 23731968 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram arm (ANH used for predicted probability of transfusion ≥ 50%)
Number of subjects: 114
Study 23731968 — intervention group
Group type: COMPARATOR
Intervention: Clinical arm (ANH used for resection of ≥ 3 liver segments)
Number of subjects: 114
Study 20673626 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (PC)
Number of subjects: 326
Study 20673626 — intervention group
Group type: COMPARATOR
Intervention: Topotecan plus carboplatin and paclitaxel (TPC)
Number of subjects: 326
Study 19517661 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% bupivacaine
Number of subjects: 90
Study 19517661 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% bupivacaine with 0.5 mg neostigmine
Number of subjects: 90
Study 19517661 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local infiltration)
Number of subjects: 90
Study 15925049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (GnRH antagonist)
Number of subjects: 131
Study 15925049 — intervention group
Group type: COMPARATOR
Intervention: Busereline (GnRH agonist)
Number of subjects: 131
Study 12860551 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurement in symptomatic athletes
Number of subjects: 14
Study 12860551 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurement after recovery from symptoms
Number of subjects: 14
Study 12860551 — intervention group
Group type: COMPARATOR
Intervention: Bone mineral density measurement in nonathlete control subjects
Number of subjects: 14
Study 12860551 — intervention group
Group type: COMPARATOR
Intervention: Bone mineral density measurement in healthy athletes
Number of subjects: 14
Study 10828925 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational pamphlet
Number of subjects: 486
Study 10828925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 486
Study 9259041 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training with a clinical psychologist
Number of subjects: 22
Study 9259041 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 8456894 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 41
Study 8456894 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 41
Study 8456894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3757442 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (13 individuals)
Number of subjects: 23
Study 3757442 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10 individuals)
Number of subjects: 23
Study 3757442 — intervention group
Group type: COMPARATOR
Intervention: Dynamic exercise without blockade
Number of subjects: 23
Study 30246241 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation intervention
Number of subjects: 3754
Study 30246241 — intervention group
Group type: COMPARATOR
Intervention: No barriers reported
Number of subjects: 3754
Study 27181566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3641
Study 27181566 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus GPI
Number of subjects: 3641
Study 24798870 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg JNJ-41443532
Number of subjects: 89
Study 24798870 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg JNJ-41443532
Number of subjects: 89
Study 24798870 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 89
Study 24798870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 22695756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nicotine tablets (SNT)
Number of subjects: 250
Study 20484175 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene (20 mg per day)
Number of subjects: 82
Study 20484175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 18548397 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 1497
Study 18548397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1497
Study 15645186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol 50 mg (drops) followed by tramadol sustained release 100 mg orally, placebo rectally
Number of subjects: 60
Study 15645186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal tramadol 100 mg, placebo orally
Number of subjects: 60
Study 15645186 — intervention group
Group type: COMPARATOR
Intervention: Oral tramadol
Number of subjects: 60
Study 11922358 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Fixation (IF)
Number of subjects: 409
Study 11922358 — intervention group
Group type: COMPARATOR
Intervention: Arthroplasty
Number of subjects: 409
Study 9659818 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with dementia (hip fracture, hemiplegia, hemiparesis, senile dementia of Alzheimer type, multi-infarct dementia)
Number of subjects: 696
Study 9659818 — intervention group
Group type: COMPARATOR
Intervention: Osteoarthropathy patients with normal intelligence
Number of subjects: 696
Study 7626318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest (4 months)
Number of subjects: 8
Study 7626318 — intervention group
Group type: EXPERIMENTAL
Intervention: Reambulation (5-6 weeks after bed rest)
Number of subjects: 8
Study 7626318 — intervention group
Group type: EXPERIMENTAL
Intervention: Reambulation
Number of subjects: 8
Study 3382169 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 245
Study 3382169 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 245
Study 31742316 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (20 mL)
Number of subjects: 20
Study 31742316 — intervention group
Group type: EXPERIMENTAL
Intervention: C8-dietary oil (2-OG + MCFAs)
Number of subjects: 20
Study 31742316 — intervention group
Group type: COMPARATOR
Intervention: Tricaprylin (MCFAs; negative control)
Number of subjects: 20
Study 31742316 — intervention group
Group type: COMPARATOR
Intervention: C8-dietary oil vs Tricaprylin
Number of subjects: 20
Study 31742316 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP response
Number of subjects: 20
Study 31742316 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal enteroendocrine responses
Number of subjects: 20
Study 30597280 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive VR surgical simulator training
Number of subjects: 16
Study 30597280 — intervention group
Group type: COMPARATOR
Intervention: Traditional introductory teaching session (non-VR group)
Number of subjects: 16
Study 28089528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel spacer (SpaceOAR system) implantation
Number of subjects: 149
Study 28089528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel spacer infiltration into the rectal wall
Number of subjects: 149
Study 28089528 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical hydrogel spacer placement
Number of subjects: 149
Study 26071975 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 2553
Study 26071975 — intervention group
Group type: COMPARATOR
Intervention: Control (no β-blocker therapy)
Number of subjects: 2553
Study 23592849 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for Teaching based on Autism Research
Number of subjects: 119
Study 23592849 — intervention group
Group type: COMPARATOR
Intervention: Structured Teaching
Number of subjects: 119
Study 21917762 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 89
Study 21917762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19853690 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise training (n = 20)
Number of subjects: 40
Study 19853690 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 16696743 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 39
Study 16696743 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 39
Study 14980926 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (ropivacaine 3.2 mg plus fentanyl 8 microg/dose) with DM 90 mg
Number of subjects: 120
Study 14980926 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-PCA (morphine 2 mg/dose) with DM 90 mg
Number of subjects: 120
Study 14980926 — intervention group
Group type: COMPARATOR
Intervention: PCEA (ropivacaine 3.2 mg plus fentanyl 8 microg/dose) with placebo
Number of subjects: 120
Study 14980926 — intervention group
Group type: COMPARATOR
Intervention: IV-PCA (morphine 2 mg/dose) with placebo
Number of subjects: 120
Study 14980926 — intervention group
Group type: EXPERIMENTAL
Intervention: DM patients
Number of subjects: 120
Study 11692213 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathologic examination in IDC patients
Number of subjects: 72
Study 11692213 — intervention group
Group type: COMPARATOR
Intervention: Histopathologic examination in comparison group (heart diseases of known causes)
Number of subjects: 72
Study 11692213 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial fibroelastosis in IDC patients
Number of subjects: 72
Study 11692213 — intervention group
Group type: COMPARATOR
Intervention: Endocardial fibroelastosis in comparison group
Number of subjects: 72
Study 11692213 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct patterns of fibrosis
Number of subjects: 72
Study 11692213 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive fibrosis presence in IDC patients
Number of subjects: 72
Study 9325588 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-based judgments
Number of subjects: 2
Study 9325588 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line judgments
Number of subjects: 2
Study 7911306 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine 50 micrograms/kg IV followed by vecuronium 60 micrograms/kg IV
Number of subjects: 40
Study 7911306 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 60 micrograms/kg IV without priming
Number of subjects: 40
Study 2860819 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 90
Study 2860819 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 90
Study 2860819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29443372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 110
Study 29443372 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 110
Study 29443372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 110
Study 29443372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg
Number of subjects: 110
Study 27863609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant natural sounds
Number of subjects: 130
Study 27863609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130
Study 27863609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pleasant natural sounds and control)
Number of subjects: 130
Study 25039272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of sildenafil 100mg and vacuum erection device
Number of subjects: 66
Study 25039272 — intervention group
Group type: COMPARATOR
Intervention: Vacuum erection device only
Number of subjects: 66
Study 22120748 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic visual noise (DVN)
Number of subjects: 0
Study 22120748 — intervention group
Group type: COMPARATOR
Intervention: Static visual noise
Number of subjects: 0
Study 22120748 — intervention group
Group type: COMPARATOR
Intervention: No interference control
Number of subjects: 0
Study 20206891 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous (cIV) furosemide
Number of subjects: 56
Study 20206891 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous (iIV) furosemide
Number of subjects: 56
Study 18555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg BID for 1 week, then 10 microg BID for the next week)
Number of subjects: 30
Study 18555933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18555933 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 30
Study 17635508 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lotion containing triethyl citrate and ethyl linoleate
Number of subjects: 40
Study 17635508 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (vehicle)
Number of subjects: 40
Study 15473116 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill plus Bobath walking training
Number of subjects: 50
Study 15473116 — intervention group
Group type: COMPARATOR
Intervention: Bobath walking training alone
Number of subjects: 50
Study 10831815 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with myelomeningocele
Number of subjects: 35
Study 10831815 — intervention group
Group type: COMPARATOR
Intervention: Normal children (control group)
Number of subjects: 35
Study 9353982 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement analysis (MA) system
Number of subjects: 0
Study 9353982 — intervention group
Group type: COMPARATOR
Intervention: Healthy people
Number of subjects: 0
Study 9353982 — intervention group
Group type: COMPARATOR
Intervention: Hemiparetic patients
Number of subjects: 0
Study 1583673 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 20
Study 1583673 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 20
Study 1583673 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 20
Study 2859075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine months' chemotherapy with rifampicin plus isoniazid supplemented by ethambutol for eight weeks
Number of subjects: 152
Study 2859075 — intervention group
Group type: COMPARATOR
Intervention: Eighteen months' chemotherapy with rifampicin plus isoniazid supplemented by ethambutol for eight weeks
Number of subjects: 152
Study 30187419 — intervention group
Group type: COMPARATOR
Intervention: American position
Number of subjects: 18
Study 30187419 — intervention group
Group type: EXPERIMENTAL
Intervention: French position
Number of subjects: 18
Study 27957668 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Meeting
Number of subjects: 143
Study 27957668 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic Choice
Number of subjects: 143
Study 27957668 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline interaction quality
Number of subjects: 143
Study 25534187 — intervention group
Group type: COMPARATOR
Intervention: CBD (16mg)
Number of subjects: 48
Study 25534187 — intervention group
Group type: COMPARATOR
Intervention: THC (8mg)
Number of subjects: 48
Study 25534187 — intervention group
Group type: COMPARATOR
Intervention: THC+CBD (8mg+16mg)
Number of subjects: 48
Study 23658561 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic dance combined with drug therapy (Hydrochlorothiazide + amiloride hydrochloride, and Amlodipine)
Number of subjects: 63
Study 23658561 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (Hydrochlorothiazide + amiloride hydrochloride, and Amlodipine)
Number of subjects: 63
Study 23658561 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups post-intervention
Number of subjects: 63
Study 21293851 — intervention group
Group type: EXPERIMENTAL
Intervention: Older fallers
Number of subjects: 3
Study 21293851 — intervention group
Group type: COMPARATOR
Intervention: Age-matched non-fallers
Number of subjects: 3
Study 21293851 — intervention group
Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 3
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom availability in treatment programs
Number of subjects: 324
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Possession of condoms
Number of subjects: 324
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Future intention to use condoms
Number of subjects: 324
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Future intention to increase condom use
Number of subjects: 324
Study 19842829 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a high-risk partner
Number of subjects: 324